MDC Scientists Show How Hematopoietic Stem Cell Development Is Regulated

These were the findings of researchers at the laboratory of Dr. Frank Rosenbauer of the Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch in cooperation with the laboratory of Professor Sten Eirik W. Jacobsen (Lund University, Sweden and the University of Oxford, England). Furthermore, the researchers showed that DNA methylation also plays a crucial role for cancer stem cells (Nature Genetics, online, doi: doi:10.1038/ng.463)*.

A group of three enzymes, the DNA methyltransferases (Dnmt) regulates the addition of methyl groups to the DNA (DNA methylation). One of these enzymes – Dnmt1 – is responsible for the maintenance of the marks with the methyl groups, the DNA methylation pattern, because the distribution of the methyl groups on the DNA decides which genes are transcribed and which are blocked. Researchers speak in this context of epigenetic information, in contrast to genetic information.

However, it was unclear until now whether DNA methylation plays a special role in the control of hematopoietic stem cell characteristics. From the HSCs all of the blood cells of the body are formed. Since blood cells have only a limited lifetime, the body must form new blood cells over and over again. The pool for this is generated by the HSCs.

In order to discover what function DNA methylation has for HSCs, the two doctoral students Ann-Marie Bröske and Lena Vockentanz of the MDC research laboratory of Dr. Rosenbauer switched off the enzyme Dnmt1 in the mice. As a result, the animals were not viable because the hematopoietic stem cell function was completely disturbed.

By contrast, when the two researchers arranged that the HSCs formed just a little Dnmt1, the animals survived, but the HSCs lost their potential for self-renewal. Moreover, the HSCs were restricted in their formation of B cells and T cells (blood cells of the lymphatic system and important cells of the immune system).

However, the HSCs were able to form red blood cells, which are important for oxygen transport and belong to the blood cells of the myeloerythroid system. In other words, the DNA methylation level regulates which blood cell lineages develop or not from a hematopoietic stem cell.

Cancer stem cells
Methylation processes also play a role in numerous cancer diseases. As the MDC researchers were able to show, the DNA methylation by the enzyme Dnmt1 also controls the development of leukemic stem cells.

If the DNA methylation level is low, cancer stem cell renewal is restricted. Moreover, the formation of leukemic cells of B-cell lineage (acute B-cell leukemia – ALL) is blocked.

The question is whether diseased stem cells can be switched off, possibly through a blockade of the enzyme Dnmt1. Dr. Rosenbauer and his research team want to make a more detailed investigation of this question in a further project.

*DNA methylation protects hematopoietic stem cell multipotency from myeloerythroid restriction
Ann-Marie Bröske1*, Lena Vockentanz1*, Shabnam Kharazi2, Matthew R. Huska1, Elena Mancini3, Marina Scheller1, Christiane Kuhl1, Andreas Enns1, Marco Prinz4, Rudolf Jaenisch5, Claus Nerlov3, Achim Leutz1, Miguel A. Andrade-Navarro1, Sten Eirik W. Jacobsen2,6 and Frank Rosenbauer1
1 Max Delbrück Center for Molecular Medicine, 13125 Berlin, Germany
2 Hematopoietic Stem Cell Laboratory, Lund Strategic Research Center for Stem Cell Biology and Cell Therapy, Lund University, Lund, Sweden
3 European Molecular Biology Laboratory, Mouse Biology Unit, Monterotondo, Italy
4 Department of Neuropathology, University of Freiburg, Freiburg, Germany
5 The Whitehead Institute, 9 Cambridge Center, Cambridge, MA, USA
6 Haematopoietic Stem Cell Laboratory, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, England.

*These authors contributed equally to this work.

Barbara Bachtler
Press and Public Affairs
Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch
Robert-Rössle-Straße 10
13125 Berlin, Germany
Phone: +49 (0) 30 94 06 – 38 96
Fax: +49 (0) 30 94 06 – 38 33
e-mail: presse@mdc-berlin.de